Quinapril Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Contact supplier
Manufacturer
Generic Availability
Quinapril Indications
Indications
Quinapril Dosage and Administration
Adult
Children
Renal Impairment
-
Avoid concomitant use of aliskiren with quinapril hydrochloride in patients with renal impairment (GFR<60 mL/min/1.73 m2).
Hepatic Impairment
-
Discontinue ACE inhibitor if patients develop jaundice or marked elevations of hepatic enzymes and administer appropriate medical follow-up.
Quinapril Contraindications
Contraindications
Quinapril Boxed Warnings
Boxed Warning
Quinapril Warnings/Precautions
Warnings/Precautions
Quinapril Pharmacokinetics
Absorption
Following oral administration, peak plasma quinapril concentrations are observed within one hour. Based on recovery of quinapril and its metabolites in urine, the extent of absorption is at least 60%.
Distribution
Approximately 97% of either quinapril or quinaprilat circulating in plasma is bound to proteins.
Elimination
Following multiple oral dosing of quinapril hydrochloride, there is an effective accumulation half-life of quinaprilat of approximately 3 hours. Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose, and has an elimination half-life in plasma of approximately 2 hours and a prolonged terminal phase with a half-life of 25 hours. In patients with renal insufficiency, the elimination half-life of quinaprilat increases as creatinine clearance decreases.
Quinapril Interactions
Interactions
Quinapril Adverse Reactions
Adverse Reactions
Quinapril Clinical Trials
See Literature
Quinapril Note
Not Applicable
Quinapril Patient Counseling
Quinapril Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Contact supplier
Manufacturer
Generic Availability
Quinapril Indications
Indications
Quinapril Dosage and Administration
Adult
Children
Renal Impairment
-
Avoid concomitant use of aliskiren with quinapril hydrochloride in patients with renal impairment (GFR<60 mL/min/1.73 m2).
Hepatic Impairment
-
Discontinue ACE inhibitor if patients develop jaundice or marked elevations of hepatic enzymes and administer appropriate medical follow-up.
Quinapril Contraindications
Contraindications
Quinapril Boxed Warnings
Boxed Warning
Quinapril Warnings/Precautions
Warnings/Precautions
Quinapril Pharmacokinetics
Absorption
Following oral administration, peak plasma quinapril concentrations are observed within one hour. Based on recovery of quinapril and its metabolites in urine, the extent of absorption is at least 60%.
Distribution
Approximately 97% of either quinapril or quinaprilat circulating in plasma is bound to proteins.
Elimination
Following multiple oral dosing of quinapril hydrochloride, there is an effective accumulation half-life of quinaprilat of approximately 3 hours. Quinaprilat is eliminated primarily by renal excretion, up to 96% of an IV dose, and has an elimination half-life in plasma of approximately 2 hours and a prolonged terminal phase with a half-life of 25 hours. In patients with renal insufficiency, the elimination half-life of quinaprilat increases as creatinine clearance decreases.
Quinapril Interactions
Interactions
Quinapril Adverse Reactions
Adverse Reactions
Quinapril Clinical Trials
See Literature
Quinapril Note
Not Applicable